1
|
Perera KS, Vanassche T, Bosch J, Giruparajah M, Swaminathan B, Mattina KR, Berkowitz SD, Arauz A, O’Donnell MJ, Ameriso SF, Hankey GJ, Yoon BW, Lavallee P, Cunha L, Shamalov N, Brouns R, Gagliardi RJ, Kasner SE, Pieroni A, Vermehren P, Kitagawa K, Wang Y, Muir K, Coutinho J, Vastagh I, Connolly SJ, Hart RG. Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. Int J Stroke 2016; 11:526-33. [DOI: 10.1177/1747493016641967] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Accepted: 01/20/2016] [Indexed: 11/17/2022]
Abstract
Background Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. Accordingly, these strokes have been designated as embolic strokes of undetermined source (ESUS). Aims We undertook an international survey to characterize the frequency and clinical features of ESUS patients across global regions. Methods Consecutive patients hospitalized for ischemic stroke were retrospectively surveyed from 19 stroke research centers in 19 different countries to collect patients meeting criteria for ESUS. Results Of 2144 patients with recent ischemic stroke, 351 (16%, 95% CI 15% to 18%) met ESUS criteria, similar across global regions (range 16% to 21%), and an additional 308 (14%) patients had incomplete evaluation required for ESUS diagnosis. The mean age of ESUS patients (62 years; SD = 15) was significantly lower than the 1793 non-ESUS ischemic stroke patients (68 years, p ≤ 0.001). Excluding patients with atrial fibrillation ( n = 590, mean age = 75 years), the mean age of the remaining 1203 non-ESUS ischemic stroke patients was 64 years ( p = 0.02 vs. ESUS patients). Among ESUS patients, hypertension, diabetes, and prior stroke were present in 64%, 25%, and 17%, respectively. Median NIHSS score was 4 (interquartile range 2–8). At discharge, 90% of ESUS patients received antiplatelet therapy and 7% received anticoagulation. Conclusions This cross-sectional global sample of patients with recent ischemic stroke shows that one-sixth met criteria for ESUS, with additional ESUS patients likely among those with incomplete diagnostic investigation. ESUS patients were relatively young with mild strokes. Antiplatelet therapy was the standard antithrombotic therapy for secondary stroke prevention in all global regions.
Collapse
Affiliation(s)
- Kanjana S Perera
- Department of Medicine (Neurology), McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Thomas Vanassche
- Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Jackie Bosch
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Mohana Giruparajah
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Balakumar Swaminathan
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Katie R Mattina
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | | | - Antonio Arauz
- Instituto Nacional de Neurologia y Neurocirugia, Mexico DF, Mexico
| | | | - Sebastian F Ameriso
- Institute for Neurological Research, Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia (FLENI), Buenos Aires, Argentina
| | - Graeme J Hankey
- School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia
| | - Byung-Woo Yoon
- Department of Neurology, Seoul National University Hospital, Seoul, Korea
| | | | - Luis Cunha
- Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - Nikolay Shamalov
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - Raf Brouns
- Universitair Ziekenhuis Brussel, Brussels, Belgium
| | | | - Scott E Kasner
- Department of Neurology, Hospital of the University of Pennsylvania, Philadephia, United States
| | - Alessio Pieroni
- Department of Neurology and Psychiatry, “Sapienza” University of Rome, Rome, Italy
| | - Philipp Vermehren
- Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany
| | - Kazuo Kitagawa
- Department of Neurology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Yongjun Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - Keith Muir
- Institute of Neuroscience and Physiology, University of Glasgow, Queen Elizabeth Hospital, Glasgow, United Kingdom
| | | | - Ildiko Vastagh
- Department of Neurology, Semmelweis University, Budapest, Hungary
| | - Stuart J Connolly
- Department of Medicine (Cardiology), Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Robert G Hart
- Department of Medicine (Neurology), McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| |
Collapse
|
2
|
Tibshirani M, Tradewell ML, Mattina KR, Minotti S, Yang W, Zhou H, Strong MJ, Hayward LJ, Durham HD. Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1. Hum Mol Genet 2014; 24:773-86. [PMID: 25274782 DOI: 10.1093/hmg/ddu494] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Mutations in the RNA-binding protein FUS/TLS (FUS) have been linked to the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Although predominantly nuclear, this heterogenous nuclear ribonuclear protein (hnRNP) has multiple functions in RNA processing including intracellular trafficking. In ALS, mutant or wild-type (WT) FUS can form neuronal cytoplasmic inclusions. Asymmetric arginine methylation of FUS by the class 1 arginine methyltransferase, protein arginine methyltransferase 1 (PRMT1), regulates nucleocytoplasmic shuttling of FUS. In motor neurons of primary spinal cord cultures, redistribution of endogenous mouse and that of ectopically expressed WT or mutant human FUS to the cytoplasm led to nuclear depletion of PRMT1, abrogating methylation of its nuclear substrates. Specifically, hypomethylation of arginine 3 of histone 4 resulted in decreased acetylation of lysine 9/14 of histone 3 and transcriptional repression. Distribution of neuronal PRMT1 coincident with FUS also was detected in vivo in the spinal cord of FUS(R495X) transgenic mice. However, nuclear PRMT1 was not stable postmortem obviating meaningful evaluation of ALS autopsy cases. This study provides evidence for loss of PRMT1 function as a consequence of cytoplasmic accumulation of FUS in the pathogenesis of ALS, including changes in the histone code regulating gene transcription.
Collapse
Affiliation(s)
- Michael Tibshirani
- Montreal Neurological Institute and Department of Neurology/Neurosurgery, McGill University, Montreal, Quebec, Canada H3A 2B4
| | - Miranda L Tradewell
- Montreal Neurological Institute and Department of Neurology/Neurosurgery, McGill University, Montreal, Quebec, Canada H3A 2B4
| | - Katie R Mattina
- Montreal Neurological Institute and Department of Neurology/Neurosurgery, McGill University, Montreal, Quebec, Canada H3A 2B4
| | - Sandra Minotti
- Montreal Neurological Institute and Department of Neurology/Neurosurgery, McGill University, Montreal, Quebec, Canada H3A 2B4
| | - Wencheng Yang
- Robarts Research Institute, Western University, London, Ontario, Canada N6A 5C1 and
| | - Hongru Zhou
- Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - Michael J Strong
- Robarts Research Institute, Western University, London, Ontario, Canada N6A 5C1 and
| | - Lawrence J Hayward
- Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - Heather D Durham
- Montreal Neurological Institute and Department of Neurology/Neurosurgery, McGill University, Montreal, Quebec, Canada H3A 2B4
| |
Collapse
|